Brokerages Set Codexis, Inc. (NASDAQ:CDXS) PT at $6.80

Shares of Codexis, Inc. (NASDAQ:CDXS) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.80.

Several research firms have weighed in on CDXS. StockNews.com upgraded shares of Codexis to a “sell” rating in a report on Tuesday, March 5th. Benchmark upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a report on Thursday, February 29th.

Institutional Investors Weigh In On Codexis

A number of hedge funds and other institutional investors have recently made changes to their positions in CDXS. GSA Capital Partners LLP bought a new position in Codexis in the third quarter valued at $786,000. Assenagon Asset Management S.A. grew its position in Codexis by 156.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,753,443 shares of the biotechnology company’s stock valued at $3,314,000 after purchasing an additional 1,071,002 shares in the last quarter. FMR LLC grew its position in Codexis by 153.7% in the third quarter. FMR LLC now owns 4,335,580 shares of the biotechnology company’s stock valued at $8,194,000 after purchasing an additional 2,626,400 shares in the last quarter. Algert Global LLC grew its position in Codexis by 8.9% in the third quarter. Algert Global LLC now owns 107,080 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 8,720 shares in the last quarter. Finally, Barclays PLC grew its position in Codexis by 262.6% in the third quarter. Barclays PLC now owns 155,055 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 112,289 shares in the last quarter. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Price Performance

Shares of NASDAQ CDXS opened at $3.49 on Tuesday. The company’s 50 day simple moving average is $3.23 and its 200 day simple moving average is $2.56. Codexis has a fifty-two week low of $1.45 and a fifty-two week high of $4.91. The firm has a market capitalization of $245.35 million, a P/E ratio of -3.14 and a beta of 2.04.

Codexis (NASDAQ:CDXS) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.18. The company had revenue of $26.56 million for the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative net margin of 108.69% and a negative return on equity of 47.58%. Sell-side analysts expect that Codexis will post -0.6 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.